Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Rheumatoid arthritis (RA) affects around 1.2% of the adult population. RA is one of the main reasons for work disability and premature retirement, thus substantially increasing social and economic burden. Biological disease-modifying antirheumatic drugs (bDMARDs) were shown to be an effective therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonek, Krzysztof, Roszkowski, Leszek, Massalska, Magdalena, Maslinski, Wlodzimierz, Ciechomska, Marzena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914976/
https://www.ncbi.nlm.nih.gov/pubmed/33557301
http://dx.doi.org/10.3390/cells10020323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914976/
https://www.ncbi.nlm.nih.gov/pubmed/33557301
http://dx.doi.org/10.3390/cells10020323

Ejemplares similares